- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06524544
진행성 요로상피암 치료에서 Pembrolizumab과 Sacituzumab Govitecan의 병용 요법과 Sacituzumab Govitecan 단독 요법을 비교하는 연구
항PD(L)1 내성 진행성 요로상피암에서 Pembrolizumab과 Sacituzumab Govitecan의 병용 대 Sacituzumab Govitecan 단독의 제3상 무작위 임상시험
This phase III trial compares the effectiveness of pembrolizumab and sacituzumab govitecan-hziy to standard of care in treating patients with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Sacituzumab govitecan-hziy is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug called govitecan-hziy. Sacituzumab attaches to TROP2 positive tumor cells in a targeted way and delivers govitecan-hziy to kill them. The usual treatment approach is treatment with chemotherapy such as cisplatin, carboplatin, gemcitabine, docetaxel or paclitaxel. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Giving pembrolizumab and sacituzumab govitecan-hziy may be more effective than usual care of carboplatin or cisplatin with gemcitabine, docetaxel or paclitaxel in treating patients with locally advanced or metastatic urothelial cancer.
연구 개요
상태
상세 설명
PRIMARY OBJECTIVE:
I. To compare overall survival (OS) between the therapy of physician choice (TPC) arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
SECONDARY OBJECTIVES:
I. To compare the progression free survival (PFS) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
II. To evaluate overall response rate (ORR) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
III. To evaluate clinical benefit rate (complete response [CR]/partial response [PR] /stable disease [SD]) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
IV. To evaluate duration of response (DoR) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
V. To evaluate toxicity of the Sacituzumab govitecan-hziy + pembrolizumab arm using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).
EXPLORATORY HEALTH RELATED QUALITY OF LIFE (HRQOL) OBJECTIVES:
I. To compare HRQOL, as assessed by the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18) summary score between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm at 6 months.
II. To compare HRQOL change from baseline, as assessed by the FBISI-18 summary score, for patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm at baseline, 3, 6, and 12 months.
III. To compare the change in patient-reported fatigue from baseline and across 3, 6, and 12 months as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) summary score; change from baseline will be compared between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm.
IV. To compare quality-adjusted survival (overall survival x health utility score assessed by the European Quality of Life Five Dimension Five Level [EQ-5D-5L]) between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm.
V. To compare time to HRQOL deterioration in global HRQOL, as measured by the FBISI-18 disease-related physical symptom subscale (FBISI-18 disease-related symptoms (DRS) in the physical emotional domains [DRS-P]), between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive TPC with carboplatin or cisplatin intravenously (IV) on day 1 and gemcitabine IV on days 1 and 8 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may alternately receive TPC with docetaxel IV on day 1 of each cycle or paclitaxel IV on either day 1 or days 1, 8, and 15 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection and computed tomography (CT) or magnetic resonance imaging (MRI) throughout the study.
ARM B: Patients receive sacituzumab govitecan-hziy IV over 1-3 hours on days 1 and 8 and pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 35 cycles or for 2 years of pembrolizumab in the absence of disease progression or unacceptable toxicity. Cycles of sacituzumab govitecan-hziy repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection, and CT or MRI throughout the study.
After completion of study treatment, patients are followed up at 30 days then once a year for 5 years from the date of randomization.
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
Arizona
-
Phoenix, Arizona, 미국, 85004
- 모병
- Cancer Center at Saint Joseph's
-
수석 연구원:
- Loretta J. Nastoupil
-
연락하다:
- Site Public Contact
- 전화번호: 720-874-1881
- 이메일: ResearchInstituteInquiries@CommonSpirit.org
-
-
California
-
Irvine, California, 미국, 92612
- 모병
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
연락하다:
- Site Public Contact
- 전화번호: 877-827-8839
- 이메일: ucstudy@uci.edu
-
수석 연구원:
- Nataliya Mar
-
Orange, California, 미국, 92868
- 모병
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 877-827-8839
- 이메일: ucstudy@uci.edu
-
수석 연구원:
- Nataliya Mar
-
-
Florida
-
Gainesville, Florida, 미국, 32610
- 모병
- UF Health Cancer Institute - Gainesville
-
수석 연구원:
- Daniel V. Araujo
-
연락하다:
- Site Public Contact
- 전화번호: 352-273-8010
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- 모병
- Emory University Hospital/Winship Cancer Institute
-
연락하다:
- Site Public Contact
- 전화번호: 404-778-1868
-
수석 연구원:
- Jacqueline T. Brown
-
Atlanta, Georgia, 미국, 30308
- 모병
- Emory University Hospital Midtown
-
연락하다:
- Site Public Contact
- 전화번호: 888-946-7447
-
수석 연구원:
- Jacqueline T. Brown
-
Atlanta, Georgia, 미국, 30342
- 모병
- Emory Saint Joseph's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 404-851-7115
-
수석 연구원:
- Jacqueline T. Brown
-
-
Idaho
-
Coeur d'Alene, Idaho, 미국, 83814
- 모병
- Kootenai Health - Coeur d'Alene
-
수석 연구원:
- John M. Schallenkamp
-
연락하다:
- Site Public Contact
- 전화번호: 406-969-6060
- 이메일: mccinfo@mtcancer.org
-
Post Falls, Idaho, 미국, 83854
- 모병
- Kootenai Clinic Cancer Services - Post Falls
-
수석 연구원:
- John M. Schallenkamp
-
연락하다:
- Site Public Contact
- 전화번호: 406-969-6060
- 이메일: mccinfo@mtcancer.org
-
Sandpoint, Idaho, 미국, 83864
- 모병
- Kootenai Clinic Cancer Services - Sandpoint
-
수석 연구원:
- John M. Schallenkamp
-
연락하다:
- Site Public Contact
- 전화번호: 406-969-6060
- 이메일: mccinfo@mtcancer.org
-
-
Illinois
-
Chicago, Illinois, 미국, 60612
- 모병
- University of Illinois
-
연락하다:
- Site Public Contact
- 전화번호: 312-355-3046
-
수석 연구원:
- Karine Tawagi
-
Danville, Illinois, 미국, 61832
- 모병
- Carle at The Riverfront
-
수석 연구원:
- Priyank P. Patel
-
연락하다:
- Site Public Contact
- 전화번호: 800-446-5532
- 이메일: Research@Carle.com
-
Decatur, Illinois, 미국, 62526
- 모병
- Cancer Care Specialists of Illinois - Decatur
-
수석 연구원:
- Bryan A. Faller
-
연락하다:
- Site Public Contact
- 전화번호: 217-876-4762
- 이메일: morganthaler.jodi@mhsil.com
-
Decatur, Illinois, 미국, 62526
- 모병
- Decatur Memorial Hospital
-
수석 연구원:
- Bryan A. Faller
-
연락하다:
- Site Public Contact
- 전화번호: 217-876-4762
- 이메일: morganthaler.jodi@mhsil.com
-
Effingham, Illinois, 미국, 62401
- 모병
- Carle Physician Group-Effingham
-
연락하다:
- Site Public Contact
- 전화번호: 800-446-5532
- 이메일: Research@carle.com
-
수석 연구원:
- Priyank P. Patel
-
Effingham, Illinois, 미국, 62401
- 모병
- Crossroads Cancer Center
-
수석 연구원:
- Bryan A. Faller
-
연락하다:
- Site Public Contact
- 전화번호: 217-876-4762
- 이메일: morganthaler.jodi@mhsil.com
-
Mattoon, Illinois, 미국, 61938
- 모병
- Carle Physician Group-Mattoon/Charleston
-
연락하다:
- Site Public Contact
- 전화번호: 800-446-5532
- 이메일: Research@carle.com
-
수석 연구원:
- Priyank P. Patel
-
Normal, Illinois, 미국, 61761
- 모병
- Carle BroMenn Medical Center
-
수석 연구원:
- Priyank P. Patel
-
연락하다:
- Site Public Contact
- 전화번호: 800-446-5532
- 이메일: Research@Carle.com
-
Normal, Illinois, 미국, 61761
- 모병
- Carle Cancer Institute Normal
-
수석 연구원:
- Priyank P. Patel
-
연락하다:
- Site Public Contact
- 전화번호: 800-446-5532
- 이메일: Research@Carle.com
-
O'Fallon, Illinois, 미국, 62269
- 모병
- Cancer Care Center of O'Fallon
-
수석 연구원:
- Bryan A. Faller
-
연락하다:
- Site Public Contact
- 전화번호: 217-876-4762
- 이메일: morganthaler.jodi@mhsil.com
-
O'Fallon, Illinois, 미국, 62269
- 모병
- HSHS Saint Elizabeth's Hospital
-
수석 연구원:
- Bryan A. Faller
-
연락하다:
- Site Public Contact
- 전화번호: 217-876-4762
- 이메일: morganthaler.jodi@mhsil.com
-
Shiloh, Illinois, 미국, 62269
- 모병
- Memorial Hospital East
-
연락하다:
- Site Public Contact
- 전화번호: 314-747-9912
- 이메일: dschwab@wustl.edu
-
수석 연구원:
- Melissa A. Reimers
-
Springfield, Illinois, 미국, 62702
- 모병
- Southern Illinois University School of Medicine
-
수석 연구원:
- Bryan A. Faller
-
연락하다:
- Site Public Contact
- 전화번호: 217-545-7929
-
Springfield, Illinois, 미국, 62702
- 모병
- Springfield Clinic
-
수석 연구원:
- Bryan A. Faller
-
연락하다:
- Site Public Contact
- 전화번호: 800-444-7541
-
Springfield, Illinois, 미국, 62781
- 모병
- Springfield Memorial Hospital
-
수석 연구원:
- Bryan A. Faller
-
연락하다:
- Site Public Contact
- 전화번호: 217-528-7541
- 이메일: pallante.beth@mhsil.com
-
Urbana, Illinois, 미국, 61801
- 모병
- Carle Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 800-446-5532
- 이메일: Research@carle.com
-
수석 연구원:
- Priyank P. Patel
-
-
Iowa
-
Ames, Iowa, 미국, 50010
- 모병
- Mary Greeley Medical Center
-
수석 연구원:
- Joseph J. Merchant
-
연락하다:
- Site Public Contact
- 전화번호: 515-956-4132
-
Ames, Iowa, 미국, 50010
- 모병
- McFarland Clinic - Ames
-
수석 연구원:
- Joseph J. Merchant
-
연락하다:
- Site Public Contact
- 전화번호: 515-239-4734
- 이메일: ksoder@mcfarlandclinic.com
-
Boone, Iowa, 미국, 50036
- 정지된
- McFarland Clinic - Boone
-
Cedar Rapids, Iowa, 미국, 52403
- 모병
- Mercy Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 319-365-4673
-
수석 연구원:
- Deborah W. Wilbur
-
Cedar Rapids, Iowa, 미국, 52403
- 모병
- Oncology Associates at Mercy Medical Center
-
수석 연구원:
- Deborah W. Wilbur
-
연락하다:
- Site Public Contact
- 전화번호: 319-363-2690
-
Fort Dodge, Iowa, 미국, 50501
- 모병
- McFarland Clinic - Trinity Cancer Center
-
수석 연구원:
- Joseph J. Merchant
-
연락하다:
- Site Public Contact
- 전화번호: 515-956-4132
-
Jefferson, Iowa, 미국, 50129
- 정지된
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, 미국, 50158
- 모병
- McFarland Clinic - Marshalltown
-
수석 연구원:
- Joseph J. Merchant
-
연락하다:
- Site Public Contact
- 전화번호: 515-956-4132
-
-
Kansas
-
Hays, Kansas, 미국, 67601
- 모병
- HaysMed
-
수석 연구원:
- Saqib Abbasi
-
연락하다:
- Site Public Contact
- 전화번호: 785-623-5774
-
Kansas City, Kansas, 미국, 66160
- 모병
- University of Kansas Cancer Center
-
수석 연구원:
- Saqib Abbasi
-
연락하다:
- Site Public Contact
- 전화번호: 913-588-3671
- 이메일: KUCC_Navigation@kumc.edu
-
Lawrence, Kansas, 미국, 66044
- 모병
- Lawrence Memorial Hospital
-
수석 연구원:
- Saqib Abbasi
-
연락하다:
- Site Public Contact
- 전화번호: 785-505-2800
- 이메일: Stephanie.Norris@LMH.ORG
-
Olathe, Kansas, 미국, 66061
- 모병
- The University of Kansas Cancer Center - Olathe
-
수석 연구원:
- Saqib Abbasi
-
연락하다:
- Site Public Contact
- 전화번호: 913-588-1569
- 이메일: OlatheCCResearch@kumc.edu
-
Overland Park, Kansas, 미국, 66210
- 모병
- University of Kansas Cancer Center-Overland Park
-
수석 연구원:
- Saqib Abbasi
-
연락하다:
- Site Public Contact
- 전화번호: 913-588-3671
- 이메일: KUCC_Navigation@kumc.edu
-
Salina, Kansas, 미국, 67401
- 모병
- Salina Regional Health Center
-
수석 연구원:
- Saqib Abbasi
-
연락하다:
- Site Public Contact
- 전화번호: 785-452-7038
- 이메일: mleepers@srhc.com
-
Topeka, Kansas, 미국, 66606
- 모병
- University of Kansas Health System Saint Francis Campus
-
수석 연구원:
- Saqib Abbasi
-
연락하다:
- Site Public Contact
- 전화번호: 785-295-8000
-
Westwood, Kansas, 미국, 66205
- 모병
- University of Kansas Hospital-Westwood Cancer Center
-
수석 연구원:
- Saqib Abbasi
-
연락하다:
- Site Public Contact
- 전화번호: 913-588-3671
- 이메일: KUCC_Navigation@kumc.edu
-
-
Kentucky
-
Louisville, Kentucky, 미국, 40202
- 모병
- The James Graham Brown Cancer Center at University of Louisville
-
수석 연구원:
- Rohit Kumar
-
연락하다:
- Site Public Contact
- 전화번호: 502-562-3429
-
Louisville, Kentucky, 미국, 40245
- 모병
- UofL Health Medical Center Northeast
-
수석 연구원:
- Rohit Kumar
-
연락하다:
- Site Public Contact
- 전화번호: 502-852-2755
- 이메일: ctoinfo@louisville.edu
-
-
Louisiana
-
Baton Rouge, Louisiana, 미국, 70809
- 모병
- Louisiana Hematology Oncology Associates LLC
-
연락하다:
- Site Public Contact
- 전화번호: 225-215-1353
- 이메일: clinicalresearch@marybird.com
-
수석 연구원:
- Scott E. Delacroix
-
Metairie, Louisiana, 미국, 70002
- 모병
- Mary Bird Perkins Cancer Center - Metairie
-
수석 연구원:
- Scott E. Delacroix
-
연락하다:
- Site Public Contact
- 전화번호: 504-584-6990
-
-
Massachusetts
-
Worcester, Massachusetts, 미국, 01655
- 모병
- UMass Memorial Medical Center - University Campus
-
연락하다:
- Site Public Contact
- 전화번호: 508-856-3216
- 이메일: cancer.research@umassmed.edu
-
수석 연구원:
- Kriti Mittal
-
-
Michigan
-
Brighton, Michigan, 미국, 48114
- 모병
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
연락하다:
- Site Public Contact
- 전화번호: 734-712-7251
- 이메일: MCRCwebsitecontactform@stjoeshealth.org
-
수석 연구원:
- Houssam Y. Hariri
-
Canton, Michigan, 미국, 48188
- 모병
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
연락하다:
- Site Public Contact
- 전화번호: 734-712-7251
- 이메일: MCRCwebsitecontactform@stjoeshealth.org
-
수석 연구원:
- Houssam Y. Hariri
-
Chelsea, Michigan, 미국, 48118
- 모병
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 734-712-7251
- 이메일: MCRCwebsitecontactform@stjoeshealth.org
-
수석 연구원:
- Houssam Y. Hariri
-
Lansing, Michigan, 미국, 48912
- 모병
- University of Michigan Health - Sparrow Lansing
-
연락하다:
- Site Public Contact
- 전화번호: 517-364-3712
- 이메일: harsha.trivedi@umhsparrow.org
-
수석 연구원:
- Houssam Y. Hariri
-
Livonia, Michigan, 미국, 48154
- 모병
- Trinity Health Saint Mary Mercy Livonia Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 734-712-7251
- 이메일: MCRCwebsitecontactform@stjoeshealth.org
-
수석 연구원:
- Houssam Y. Hariri
-
Pontiac, Michigan, 미국, 48341
- 모병
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 734-712-7251
- 이메일: MCRCwebsitecontactform@stjoeshealth.org
-
수석 연구원:
- Houssam Y. Hariri
-
Ypsilanti, Michigan, 미국, 48197
- 모병
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
연락하다:
- Site Public Contact
- 전화번호: 734-712-7251
- 이메일: MCRCwebsitecontactform@stjoeshealth.org
-
수석 연구원:
- Houssam Y. Hariri
-
-
Minnesota
-
Brainerd, Minnesota, 미국, 56401
- 모병
- Essentia Health Saint Joseph's Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 218-786-3308
- 이메일: CancerTrials@EssentiaHealth.org
-
수석 연구원:
- Bret E. Friday
-
Coon Rapids, Minnesota, 미국, 55433
- 모병
- Mercy Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 952-993-1517
- 이메일: mmcorc@healthpartners.com
-
수석 연구원:
- David M. King
-
Deer River, Minnesota, 미국, 56636
- 모병
- Essentia Health - Deer River Clinic
-
연락하다:
- Site Public Contact
- 전화번호: 218-786-3308
- 이메일: CancerTrials@EssentiaHealth.org
-
수석 연구원:
- Bret E. Friday
-
Duluth, Minnesota, 미국, 55805
- 모병
- Essentia Health Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 218-786-3308
- 이메일: CancerTrials@EssentiaHealth.org
-
수석 연구원:
- Bret E. Friday
-
Edina, Minnesota, 미국, 55435
- 모병
- Fairview Southdale Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 952-993-1517
- 이메일: mmcorc@healthpartners.com
-
수석 연구원:
- David M. King
-
Edina, Minnesota, 미국, 55435
- 모병
- Minnesota Oncology - Edina
-
연락하다:
- Site Public Contact
- 전화번호: 952-993-1517
- 이메일: mmcorc@healthpartners.com
-
수석 연구원:
- David M. King
-
Hibbing, Minnesota, 미국, 55746
- 모병
- Essentia Health Hibbing Clinic
-
수석 연구원:
- Bret E. Friday
-
연락하다:
- Site Public Contact
- 전화번호: 218-786-3308
-
Marshall, Minnesota, 미국, 56258
- 모병
- Avera Cancer Institute at Marshall
-
연락하다:
- Site Public Contact
- 전화번호: 605-322-3095
- 이메일: OncRegulatory@avera.org
-
수석 연구원:
- Ryan A. Vaca
-
Minneapolis, Minnesota, 미국, 55407
- 모병
- Abbott-Northwestern Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 952-993-1517
- 이메일: mmcorc@healthpartners.com
-
수석 연구원:
- David M. King
-
Saint Louis Park, Minnesota, 미국, 55416
- 모병
- Park Nicollet Clinic - Saint Louis Park
-
연락하다:
- Site Public Contact
- 전화번호: 952-993-1517
- 이메일: mmcorc@healthpartners.com
-
수석 연구원:
- David M. King
-
Saint Paul, Minnesota, 미국, 55101
- 모병
- Regions Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 952-993-1517
- 이메일: mmcorc@healthpartners.com
-
수석 연구원:
- David M. King
-
Saint Paul, Minnesota, 미국, 55102
- 모병
- United Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 952-993-1517
- 이메일: mmcorc@healthpartners.com
-
수석 연구원:
- David M. King
-
Sandstone, Minnesota, 미국, 55072
- 모병
- Essentia Health Sandstone
-
연락하다:
- Site Public Contact
- 전화번호: 218-786-3308
- 이메일: CancerTrials@EssentiaHealth.org
-
수석 연구원:
- Bret E. Friday
-
Virginia, Minnesota, 미국, 55792
- 모병
- Essentia Health Virginia Clinic
-
연락하다:
- Site Public Contact
- 전화번호: 218-786-3308
- 이메일: CancerTrials@EssentiaHealth.org
-
수석 연구원:
- Bret E. Friday
-
-
Missouri
-
Cape Girardeau, Missouri, 미국, 63703
- 모병
- Saint Francis Medical Center
-
수석 연구원:
- Bryan A. Faller
-
연락하다:
- Site Public Contact
- 전화번호: 573-334-2230
- 이메일: sfmc@sfmc.net
-
City of Saint Peters, Missouri, 미국, 63376
- 모병
- Siteman Cancer Center at Saint Peters Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 800-600-3606
- 이메일: info@siteman.wustl.edu
-
수석 연구원:
- Melissa A. Reimers
-
Creve Coeur, Missouri, 미국, 63141
- 모병
- Siteman Cancer Center at West County Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 800-600-3606
- 이메일: info@siteman.wustl.edu
-
수석 연구원:
- Melissa A. Reimers
-
Farmington, Missouri, 미국, 63640
- 모병
- Parkland Health Center - Farmington
-
수석 연구원:
- Bryan A. Faller
-
연락하다:
- Site Public Contact
- 전화번호: 314-996-5569
-
Kansas City, Missouri, 미국, 64154
- 모병
- University of Kansas Cancer Center - North
-
수석 연구원:
- Saqib Abbasi
-
연락하다:
- Site Public Contact
- 전화번호: 913-588-3671
- 이메일: KUCC_Navigation@kumc.edu
-
Kansas City, Missouri, 미국, 64108
- 모병
- University Health Truman Medical Center
-
수석 연구원:
- Saqib Abbasi
-
연락하다:
- Site Public Contact
- 전화번호: 816-404-4375
-
Kansas City, Missouri, 미국, 64116
- 모병
- University of Kansas Cancer Center - Briarcliff
-
수석 연구원:
- Saqib Abbasi
-
연락하다:
- Site Public Contact
- 전화번호: 913-588-3671
-
Lee's Summit, Missouri, 미국, 64064
- 모병
- University of Kansas Cancer Center - Lee's Summit
-
수석 연구원:
- Saqib Abbasi
-
연락하다:
- Site Public Contact
- 전화번호: 913-588-3671
- 이메일: KUCC_Navigation@kumc.edu
-
Sainte Genevieve, Missouri, 미국, 63670
- 모병
- Sainte Genevieve County Memorial Hospital
-
수석 연구원:
- Bryan A. Faller
-
연락하다:
- Site Public Contact
- 전화번호: 314-996-5569
-
St Louis, Missouri, 미국, 63110
- 모병
- Washington University School of Medicine
-
연락하다:
- Site Public Contact
- 전화번호: 800-600-3606
- 이메일: info@siteman.wustl.edu
-
수석 연구원:
- Melissa A. Reimers
-
St Louis, Missouri, 미국, 63129
- 모병
- Siteman Cancer Center-South County
-
연락하다:
- Site Public Contact
- 전화번호: 800-600-3606
- 이메일: info@siteman.wustl.edu
-
수석 연구원:
- Melissa A. Reimers
-
St Louis, Missouri, 미국, 63136
- 모병
- Siteman Cancer Center at Christian Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 800-600-3606
- 이메일: info@siteman.wustl.edu
-
수석 연구원:
- Melissa A. Reimers
-
St Louis, Missouri, 미국, 63131
- 모병
- Missouri Baptist Medical Center
-
수석 연구원:
- Bryan A. Faller
-
연락하다:
- Site Public Contact
- 전화번호: 314-996-5569
-
Sullivan, Missouri, 미국, 63080
- 모병
- Missouri Baptist Sullivan Hospital
-
수석 연구원:
- Bryan A. Faller
-
연락하다:
- Site Public Contact
- 전화번호: 314-996-5569
-
-
Montana
-
Anaconda, Montana, 미국, 59711
- 모병
- Community Hospital of Anaconda
-
수석 연구원:
- John M. Schallenkamp
-
연락하다:
- Site Public Contact
- 전화번호: 406-969-6060
- 이메일: mccinfo@mtcancer.org
-
Billings, Montana, 미국, 59101
- 모병
- Billings Clinic Cancer Center
-
수석 연구원:
- John M. Schallenkamp
-
연락하다:
- Site Public Contact
- 전화번호: 800-996-2663
- 이메일: research@billingsclinic.org
-
Bozeman, Montana, 미국, 59715
- 모병
- Bozeman Health Deaconess Hospital
-
수석 연구원:
- John M. Schallenkamp
-
연락하다:
- Site Public Contact
- 전화번호: 406-969-6060
- 이메일: mccinfo@mtcancer.org
-
Great Falls, Montana, 미국, 59405
- 모병
- Benefis Sletten Cancer Institute
-
수석 연구원:
- John M. Schallenkamp
-
연락하다:
- Site Public Contact
- 전화번호: 406-969-6060
- 이메일: mccinfo@mtcancer.org
-
Kalispell, Montana, 미국, 59901
- 모병
- Logan Health Medical Center
-
수석 연구원:
- John M. Schallenkamp
-
연락하다:
- Site Public Contact
- 전화번호: 406-969-6060
- 이메일: mccinfo@mtcancer.org
-
Missoula, Montana, 미국, 59804
- 모병
- Community Medical Center
-
수석 연구원:
- John M. Schallenkamp
-
연락하다:
- Site Public Contact
- 전화번호: 406-969-6060
- 이메일: mccinfo@mtcancer.org
-
-
New Hampshire
-
Lebanon, New Hampshire, 미국, 03756
- 모병
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 800-639-6918
- 이메일: cancer.research.nurse@dartmouth.edu
-
수석 연구원:
- Jacob B. Reibel
-
-
New Jersey
-
Livingston, New Jersey, 미국, 07039
- 모병
- Cooperman Barnabas Medical Center
-
수석 연구원:
- Biren Saraiya
-
연락하다:
- Site Public Contact
- 전화번호: 973-322-5200
-
Long Branch, New Jersey, 미국, 07740
- 모병
- Monmouth Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 732-923-6564
- 이메일: mary.danish@rwjbh.org
-
수석 연구원:
- Biren Saraiya
-
New Brunswick, New Jersey, 미국, 08903
- 모병
- Rutgers Cancer Institute of New Jersey
-
연락하다:
- Site Public Contact
- 전화번호: 732-235-7356
-
수석 연구원:
- Biren Saraiya
-
Newark, New Jersey, 미국, 07101
- 모병
- Rutgers New Jersey Medical School
-
연락하다:
- Site Public Contact
- 전화번호: 732-235-7356
-
수석 연구원:
- Biren Saraiya
-
Somerville, New Jersey, 미국, 08876
- 모병
- Robert Wood Johnson University Hospital Somerset
-
수석 연구원:
- Biren Saraiya
-
연락하다:
- Site Public Contact
- 전화번호: 908-685-2481
- 이메일: Siby.Varughese@rwjbh.org
-
Toms River, New Jersey, 미국, 08755
- 모병
- Community Medical Center
-
수석 연구원:
- Biren Saraiya
-
연락하다:
- Site Public Contact
- 전화번호: 732-557-8294
- 이메일: Lennette.Gonzales@rwjbh.org
-
-
New York
-
Buffalo, New York, 미국, 14263
- 모병
- Roswell Park Cancer Institute
-
연락하다:
- Site Public Contact
- 전화번호: 800-767-9355
- 이메일: askroswell@roswellpark.org
-
수석 연구원:
- Ellis G. Levine
-
Stony Brook, New York, 미국, 11794
- 모병
- Stony Brook University Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 800-862-2215
-
수석 연구원:
- Judy Huang
-
Williamsville, New York, 미국, 14221
- 모병
- Roswell Park Amherst Center
-
연락하다:
- Site Public Contact
- 전화번호: 800-767-9355
- 이메일: askroswell@roswellpark.org
-
수석 연구원:
- Ellis G. Levine
-
-
North Carolina
-
Hendersonville, North Carolina, 미국, 28791
- 모병
- Margaret R Pardee Memorial Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 828-696-4716
- 이메일: pardeecancerresearch@unchealth.unc.edu
-
수석 연구원:
- John K. Hill
-
-
North Dakota
-
Fargo, North Dakota, 미국, 58103
- 모병
- Essentia Health Cancer Center-South University Clinic
-
연락하다:
- Site Public Contact
- 전화번호: 218-786-3308
- 이메일: CancerTrials@EssentiaHealth.org
-
수석 연구원:
- Bret E. Friday
-
-
Ohio
-
Columbus, Ohio, 미국, 43210
- 모병
- Ohio State University Comprehensive Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 800-293-5066
- 이메일: Jamesline@osumc.edu
-
수석 연구원:
- Yuanquan Yang
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73104
- 모병
- University of Oklahoma Health Sciences Center
-
연락하다:
- Site Public Contact
- 전화번호: 405-271-8777
- 이메일: ou-clinical-trials@ouhsc.edu
-
수석 연구원:
- Adanma Anji Ayanambakkam Attanathi
-
-
Pennsylvania
-
Danville, Pennsylvania, 미국, 17822
- 모병
- Geisinger Medical Center
-
수석 연구원:
- Sorab Gupta
-
연락하다:
- Site Public Contact
- 전화번호: 570-271-5251
- 이메일: cancerresearch@geisinger.edu
-
Dickson City, Pennsylvania, 미국, 18519
- 모병
- Geisinger Cancer Center Dickson City
-
수석 연구원:
- Sorab Gupta
-
연락하다:
- Site Public Contact
- 전화번호: 877-204-6081
- 이메일: cancerresearch@geisinger.edu
-
Erie, Pennsylvania, 미국, 16505
- 모병
- UPMC Hillman Cancer Center Erie
-
수석 연구원:
- Leonard J. Appleman
-
연락하다:
- Site Public Contact
- 전화번호: 412-864-7716
- 이메일: ClinicalResearchServices@upmc.edu
-
Erie, Pennsylvania, 미국, 16544
- 모병
- Saint Vincent Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 814-452-5000
-
수석 연구원:
- Alexander Helfand
-
Greensburg, Pennsylvania, 미국, 15601
- 모병
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
연락하다:
- Site Public Contact
- 전화번호: 724-838-1900
-
수석 연구원:
- Leonard J. Appleman
-
Harrisburg, Pennsylvania, 미국, 17109
- 모병
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
연락하다:
- Site Public Contact
- 전화번호: 717-724-6765
- 이메일: klitchfield@PINNACLEHEALTH.org
-
수석 연구원:
- Leonard J. Appleman
-
Hershey, Pennsylvania, 미국, 17033-0850
- 모병
- Penn State Milton S Hershey Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 717-531-3779
- 이메일: CTO@hmc.psu.edu
-
수석 연구원:
- Monika Joshi
-
Indiana, Pennsylvania, 미국, 15701
- 모병
- IRMC Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 412-389-5208
- 이메일: haneydl@upmc.edu
-
수석 연구원:
- Leonard J. Appleman
-
Jefferson Hills, Pennsylvania, 미국, 15025
- 모병
- Jefferson Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 412-359-3043
- 이메일: ddefazio@wpahs.org
-
수석 연구원:
- Alexander Helfand
-
Lewisburg, Pennsylvania, 미국, 17837
- 모병
- Geisinger Medical Oncology-Lewisburg
-
수석 연구원:
- Sorab Gupta
-
연락하다:
- Site Public Contact
- 전화번호: 570-523-9200
- 이메일: cancerresearch@geisinger.edu
-
Mechanicsburg, Pennsylvania, 미국, 17050
- 모병
- UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
-
연락하다:
- Site Public Contact
- 전화번호: 412-389-5208
- 이메일: haneydl@upmc.edu
-
수석 연구원:
- Leonard J. Appleman
-
Monroeville, Pennsylvania, 미국, 15146
- 모병
- Forbes Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 412-858-7746
-
수석 연구원:
- Alexander Helfand
-
Monroeville, Pennsylvania, 미국, 15146
- 모병
- UPMC Hillman Cancer Center - Monroeville
-
수석 연구원:
- Leonard J. Appleman
-
연락하다:
- Site Public Contact
- 전화번호: 412-864-7716
- 이메일: ClinicalResearchServices@upmc.edu
-
Natrona Heights, Pennsylvania, 미국, 15065
- 모병
- Allegheny Valley Hospital
-
연락하다:
- Site Public Contact
- 이메일: Dawnmarie.DeFazio@ahn.org
-
수석 연구원:
- Alexander Helfand
-
Pittsburgh, Pennsylvania, 미국, 15224
- 모병
- West Penn Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 412-578-5000
-
수석 연구원:
- Alexander Helfand
-
Pittsburgh, Pennsylvania, 미국, 15215
- 모병
- UPMC-Saint Margaret
-
연락하다:
- Site Public Contact
- 전화번호: 412-784-4900
-
수석 연구원:
- Leonard J. Appleman
-
Pittsburgh, Pennsylvania, 미국, 15237
- 모병
- UPMC-Passavant Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 412-367-6454
-
수석 연구원:
- Leonard J. Appleman
-
Pittsburgh, Pennsylvania, 미국, 15212
- 모병
- Allegheny General Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 877-284-2000
-
수석 연구원:
- Alexander Helfand
-
Pittsburgh, Pennsylvania, 미국, 15232
- 모병
- UPMC Hillman Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 412-647-8073
-
수석 연구원:
- Leonard J. Appleman
-
Seneca, Pennsylvania, 미국, 16346
- 모병
- UPMC Cancer Center at UPMC Northwest
-
연락하다:
- Site Public Contact
- 전화번호: 814-676-7900
-
수석 연구원:
- Leonard J. Appleman
-
Uniontown, Pennsylvania, 미국, 15401
- 모병
- UPMC Cancer Center-Uniontown
-
연락하다:
- Site Public Contact
- 이메일: ecog.rss@jimmy.harvard.edu
-
수석 연구원:
- Leonard J. Appleman
-
Washington, Pennsylvania, 미국, 15301
- 모병
- UPMC Cancer Center-Washington
-
연락하다:
- Site Public Contact
- 이메일: ecog.rss@jimmy.harvard.edu
-
수석 연구원:
- Leonard J. Appleman
-
West Reading, Pennsylvania, 미국, 19611
- 모병
- Reading Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 610-988-9323
-
수석 연구원:
- Terrence P. Cescon
-
Wexford, Pennsylvania, 미국, 15090
- 모병
- Wexford Health and Wellness Pavilion
-
연락하다:
- Site Public Contact
- 이메일: Dawnmarie.DeFazio@ahn.org
-
수석 연구원:
- Alexander Helfand
-
Wilkes-Barre, Pennsylvania, 미국, 18711
- 모병
- Geisinger Wyoming Valley/Henry Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 570-271-5251
- 이메일: HemonCCTrials@geisinger.edu
-
수석 연구원:
- Sorab Gupta
-
-
South Dakota
-
Aberdeen, South Dakota, 미국, 57401
- 모병
- Avera Cancer Institute-Aberdeen
-
연락하다:
- Site Public Contact
- 전화번호: 605-622-8700
- 이메일: oncregulatory@avera.org
-
수석 연구원:
- Ryan A. Vaca
-
Mitchell, South Dakota, 미국, 57301
- 모병
- Avera Cancer Institute - Mitchell
-
연락하다:
- Site Public Contact
- 전화번호: 605-322-3096
- 이메일: OncRegulatory@avera.org
-
수석 연구원:
- Ryan A. Vaca
-
Pierre, South Dakota, 미국, 57501
- 모병
- Avera Cancer Institute at Pierre
-
연락하다:
- Site Public Contact
- 전화번호: 605-322-3095
- 이메일: OncRegulatory@avera.org
-
수석 연구원:
- Ryan A. Vaca
-
Sioux Falls, South Dakota, 미국, 57105
- 모병
- Avera Cancer Institute
-
연락하다:
- Site Public Contact
- 전화번호: 605-322-3095
- 이메일: OncRegulatory@avera.org
-
수석 연구원:
- Ryan A. Vaca
-
Yankton, South Dakota, 미국, 57078
- 모병
- Avera Cancer Institute at Yankton
-
수석 연구원:
- Ryan A. Vaca
-
연락하다:
- Site Public Contact
- 전화번호: 605-655-1800
- 이메일: OncRegulatory@avera.org
-
-
Texas
-
Baytown, Texas, 미국, 77521
- 모병
- Houston Methodist San Jacinto Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 888-823-5923
- 이메일: ctsucontact@westat.com
-
수석 연구원:
- Patrick E. Prath
-
Cypress, Texas, 미국, 77429
- 모병
- Houston Methodist Cypress Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 346-356-1413
- 이메일: irb@houstonmethodist.org
-
수석 연구원:
- Patrick E. Prath
-
Dallas, Texas, 미국, 75390
- 모병
- UT Southwestern/Simmons Cancer Center-Dallas
-
연락하다:
- Site Public Contact
- 전화번호: 214-648-7097
- 이메일: canceranswerline@UTSouthwestern.edu
-
수석 연구원:
- Suzanne M. Cole
-
Dallas, Texas, 미국, 75235
- 모병
- Parkland Memorial Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 214-590-5582
- 이메일: canceranswerline@UTSouthwestern.edu
-
수석 연구원:
- Suzanne M. Cole
-
Dallas, Texas, 미국, 75237
- 모병
- UT Southwestern Simmons Cancer Center - RedBird
-
수석 연구원:
- Suzanne M. Cole
-
연락하다:
- Site Public Contact
- 전화번호: 214-648-7097
- 이메일: canceranswerline@utsouthwestern.edu
-
Fort Worth, Texas, 미국, 76104
- 모병
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
연락하다:
- Site Public Contact
- 전화번호: 214-648-7097
- 이메일: canceranswerline@UTSouthwestern.edu
-
수석 연구원:
- Suzanne M. Cole
-
Houston, Texas, 미국, 77030
- 모병
- Houston Methodist Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 713-790-2700
-
수석 연구원:
- Patrick E. Prath
-
Houston, Texas, 미국, 77070
- 모병
- Methodist Willowbrook Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 888-823-5923
- 이메일: ctsucontact@westat.com
-
수석 연구원:
- Patrick E. Prath
-
Houston, Texas, 미국, 77094
- 모병
- Houston Methodist West Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 832-522-2873
-
수석 연구원:
- Patrick E. Prath
-
Nassau Bay, Texas, 미국, 77058
- 모병
- Houston Methodist Saint John Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 888-823-5923
- 이메일: ctsucontact@westat.com
-
수석 연구원:
- Patrick E. Prath
-
Richardson, Texas, 미국, 75080
- 모병
- UT Southwestern Clinical Center at Richardson/Plano
-
연락하다:
- Site Public Contact
- 전화번호: 972-669-7044
- 이메일: Suzanne.cole@utsouthwestern.edu
-
수석 연구원:
- Suzanne M. Cole
-
Sugar Land, Texas, 미국, 77479
- 모병
- Houston Methodist Sugar Land Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 281-242-2873
-
수석 연구원:
- Patrick E. Prath
-
The Woodlands, Texas, 미국, 77385
- 모병
- Houston Methodist The Woodlands Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 713-790-2700
- 이메일: hmthewoodlands@houstonmethodist.org
-
수석 연구원:
- Patrick E. Prath
-
-
Vermont
-
Berlin Corners, Vermont, 미국, 05602
- 모병
- Central Vermont Medical Center/National Life Cancer Treatment
-
연락하다:
- Site Public Contact
- 전화번호: 802-225-5400
-
수석 연구원:
- Rahul Anil
-
Burlington, Vermont, 미국, 05401
- 모병
- University of Vermont Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 802-656-4101
- 이메일: rpo@uvm.edu
-
수석 연구원:
- Rahul Anil
-
Burlington, Vermont, 미국, 05405
- 모병
- University of Vermont and State Agricultural College
-
연락하다:
- Site Public Contact
- 전화번호: 802-656-8990
- 이메일: rpo@uvm.edu
-
수석 연구원:
- Rahul Anil
-
Saint Johnsbury, Vermont, 미국, 05819
- 모병
- Dartmouth Cancer Center - North
-
연락하다:
- Site Public Contact
- 전화번호: 800-639-6918
- 이메일: cancer.research.nurse@hitchcock.org
-
수석 연구원:
- Jacob B. Reibel
-
-
Virginia
-
Fredericksburg, Virginia, 미국, 22408
- 모병
- Hematology Oncology Associates of Fredericksburg Inc
-
연락하다:
- Site Public Contact
- 전화번호: 540-371-0079
- 이메일: cvaughn@hoafredericksburg.com
-
수석 연구원:
- Asit K. Paul
-
Richmond, Virginia, 미국, 23229
- 모병
- Virginia Cancer Institute
-
연락하다:
- Site Public Contact
- 전화번호: 804-287-3000
- 이메일: smoore@vacancer.com
-
수석 연구원:
- Asit K. Paul
-
Richmond, Virginia, 미국, 23235
- 모병
- VCU Massey Cancer Center at Stony Point
-
연락하다:
- Site Public Contact
- 이메일: ctoclinops@vcu.edu
-
수석 연구원:
- Asit K. Paul
-
Richmond, Virginia, 미국, 23298
- 모병
- VCU Massey Comprehensive Cancer Center
-
수석 연구원:
- Asit K. Paul
-
연락하다:
- Site Public Contact
- 전화번호: 804-628-6430
- 이메일: CTOclinops@vcu.edu
-
-
Washington
-
Bellevue, Washington, 미국, 98004
- 모병
- FHCC Overlake
-
연락하다:
- Site Public Contact
- 전화번호: 425-454-2148
-
수석 연구원:
- Mikhail G. Perlov
-
Kirkland, Washington, 미국, 98034
- 모병
- FHCC at EvergreenHealth
-
수석 연구원:
- Prakash Varadarajan
-
연락하다:
- Site Public Contact
- 전화번호: 425-899-6000
-
Seattle, Washington, 미국, 98195
- 모병
- University of Washington Medical Center - Montlake
-
연락하다:
- Site Public Contact
- 전화번호: 800-804-8824
-
수석 연구원:
- Petros Grivas
-
Seattle, Washington, 미국, 98109
- 모병
- Fred Hutchinson Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 800-804-8824
-
수석 연구원:
- Petros Grivas
-
Seattle, Washington, 미국, 98133
- 모병
- FHCC at Northwest Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 206-606-5800
-
수석 연구원:
- Nellowe Candelario
-
-
West Virginia
-
Charleston, West Virginia, 미국, 25304
- 모병
- Vandalia Health/CAMC Institute for Academic Medicine
-
수석 연구원:
- Kok Hoe Chan
-
연락하다:
- Site Public Contact
- 전화번호: 304-388-9944
- 이메일: CAMCClinicalTrials@vandaliahealth.org
-
-
Wisconsin
-
Appleton, Wisconsin, 미국, 54911
- 모병
- ThedaCare Regional Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 920-364-3604
- 이메일: ResearchDept@thedacare.org
-
수석 연구원:
- Joyce Philip
-
Ashland, Wisconsin, 미국, 54806
- 모병
- Duluth Clinic Ashland
-
연락하다:
- Site Public Contact
- 전화번호: 218-786-3308
- 이메일: CancerTrials@EssentiaHealth.org
-
수석 연구원:
- Bret E. Friday
-
La Crosse, Wisconsin, 미국, 54601
- 모병
- Gundersen Lutheran Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 608-775-2385
- 이메일: cancerctr@gundersenhealth.org
-
수석 연구원:
- Kurt Oettel
-
New Richmond, Wisconsin, 미국, 54017
- 모병
- Cancer Center of Western Wisconsin
-
연락하다:
- Site Public Contact
- 전화번호: 952-993-1517
- 이메일: mmcorc@healthpartners.com
-
수석 연구원:
- David M. King
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Patient must be ≥ 18 years of age
-
Patient must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
-
Patient must have locally advanced (unresectable and/or not amenable to curative intent therapy) or metastatic urothelial cancer
-
Patient must have histologically (or based on urine cytology) proven conventional urothelial carcinoma (UC) of any urinary tract origin [any histologic subtype except neuroendocrine (small or large cell)] are permitted so long as tumors include ≥ 1% conventional urothelial histology). NOTE: Pure non-urothelial histology is excluded
-
Patient must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Baseline imaging must be obtained ≤ 35 days prior to randomization
-
Patient must have the following prior treatment(s). Patient must have had progression on or after the immediate prior anti-cancer therapy
-
Patient must have had prior exposure to anti-PD(L)1 therapy [anti -PD(L)1 monotherapy or as a combination regimen in any disease/therapy setting for UC]. Patients must have received at least 1 dose of anti-PD(L)1 therapy
- NOTE: Anti-PD(L)1 therapy does not need to be the most recent therapy received prior to enrollment on this protocol
- NOTE: Patient must not have had progression within 12 weeks of starting their first anti-PD(L) 1 therapy, even if anti-PD-(L)1 treatment was given in more than one lines of therapy
-
Patient must have had ≥ 1 line of systemic therapy given in the advanced/metastatic disease setting, except for patients who had received anti-PD(L)1 + enfortumab vedotin in the localized disease setting (e.g., neoadjuvant and/or adjuvant) and had cancer progression within 12 months from the last systemic therapy dose
-
For tumors with known FGFR3+ susceptible alteration (for FGFR inhibitor), patients must have received a prior FGFR inhibitor unless contraindicated per physician discretion
-
Patient must have received prior enfortumab vedotin or any other Nectin-4 directed therapy or other MMAE-containing therapy in any disease/therapy setting unless contraindicated per physician
-
Patient must have had no prior exposure to Sacituzumab govitecan-hziy or other TROP-2 directed therapies or antibody-drug conjugate that contains topo-isomerase I inhibitor, e.g. trastuzumab deruxtecan
-
Patient must have Bellmunt score of 0-2. The Bellmunt score assesses a patient's risk and is calculated based on ECOG PS, hemoglobin level and presence of liver metastases
-
Patient must not have history of grade 3-4 immune-related adverse events on prior anti-PD1/L1, except for endocrinopathies on adequate hormone therapy repletion and/or clinically insignificant laboratory abnormalities
-
Patient must have recovered (i.e., ≤ grade 1) from clinically significant AEs due to previously administered systemic therapy agent, except for endocrinopathies on adequate hormone therapy repletion
-
NOTE: Patients with ≤ grade 2 neuropathy, any grade of alopecia, or any grade of non-clinically significant laboratory abnormality are exceptions to this criterion and are allowed in this trial.
-
Examples of non-clinically significant laboratory abnormalities include, but are not limited to:
- Lymphopenia or monopenia
- Lymphocytosis or monocytosis
- Increase in amylase or lipase with no clinical correlation
- Any other abnormal laboratory findings that have no clinical relevance per the treating investigator.
-
NOTE: If patient has undergone major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to randomization
-
-
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). Patient must not nurse infants while on protocol treatment and for 4 months after the last dose of protocol treatment
-
Patient must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. Patients of childbearing potential must continue contraceptive method(s) or abstain for 6 months after the last dose of protocol treatment. Patients with partners who could become pregnant should use effective contraception during therapy and for 3 months after the last dose of protocol treatment
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
-
Absolute neutrophil count (ANC) ≥ 1,500/uL (obtained ≤ 14 days prior to randomization)
-
Platelets ≥ 100,000/uL (obtained ≤ 14 days prior to randomization)
-
Albumin ≥ 3 g/dL (obtained ≤ 14 days prior to randomization)
-
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (obtained ≤ 14 days prior to randomization)
-
Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) ≤ 3 × institutional ULN or ≤ 5.0 x institutional ULN if known liver metastases (obtained ≤ 14 days prior to randomization)
-
Creatinine clearance (CrCl) ≥ 30 mL/min (obtained ≤ 14 days prior to randomization) NOTE: CrCl is estimated using the Cockcroft-Gault formula (or can be measured by 24-hour urine collection if needed)
-
Hemoglobin (Hb) ≥ 8.5 g/dl (obtained ≤ 14 days prior to randomization)
-
Patient must not have a known genetic UGT1A1 *28/*28 or *6/*6 homozygous variant genotype. Patients with homozygous variant types are considered poor metabolizers and are at higher risk for severe adverse events when compared to wild-type. Patients with heterozygous UGT1A1 variants (i.e. *1/*28 or *1/*6) are eligible and should be counseled accordingly and be very closely monitored if randomized to the sacituzumab govitecan arm
- NOTE: If a patient's UGT1A1 status is unknown, they are eligible to enroll (the study does not require this test as part of screening)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with history of hepatitis C virus (HCV) infection must have been treated and considered cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and are not using steroids > 10 mg of prednisone (or equivalent) daily for brain metastases for at least 7 days prior to randomization
-
Patients with prior or concurrent malignancy that is not considered clinically significant and whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen (at the discretion of the treating physician) are eligible
-
Patient must not be on systemic immunosuppressive medication, including steroids (if doses exceed the equivalent of prednisone 10 mg daily). Short courses of steroids, e.g. "burst", which are discontinued prior to randomization are acceptable. Patients on inhaled, intranasal, intra-articular and/or topical steroids are eligible
-
Patient must be English or Spanish speaking to be eligible for the HRQOL component of the study.
- NOTE: Sites cannot translate the associated HRQOL forms
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Arm I (TPC chemotherapy)
Patients receive TPC with carboplatin or cisplatin IV on day 1 and gemcitabine IV on days 1 and 8 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may alternately receive TPC with docetaxel IV on day 1 of each cycle or paclitaxel IV on either day 1 or days 1, 8, and 15 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection and CT or MRI throughout the study. |
Given IV
다른 이름들:
Given IV
다른 이름들:
Given IV
다른 이름들:
Given IV
다른 이름들:
Undergo blood sample collection
다른 이름들:
Undergo CT
다른 이름들:
Undergo MRI
다른 이름들:
Ancillary studies Given IV
다른 이름들:
|
|
실험적: Arm II (pembrolizumab, sacituzumab govitecan-hziy)
Patients receive pembrolizumab IV over 30 minutes on day 1 and sacituzumab govitecan-hziy IV over 1-3 hours on days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection, and CT or MRI throughout the study. |
Undergo blood sample collection
다른 이름들:
Undergo CT
다른 이름들:
Undergo MRI
다른 이름들:
Ancillary studies Given IV
다른 이름들:
Given IV
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall survival (OS)
기간: From randomization to death due to any cause, assessed up to 5 years
|
OS will be characterized with the method of Kaplan-Meier and will be compared between the two treatment arms using stratified log-rank test. The hazard ratio (HR) will be estimated, and a 95% confidence interval (CI) will be reported. |
From randomization to death due to any cause, assessed up to 5 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-free survival (PFS)
기간: From randomization to the earlier progression or death due to any cause, assessed up to 5 years
|
PFS will be assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. PFS will be characterized with the method of Kaplan-Meier and will be compared between the two treatment arms using stratified log-rank test. The HR will be estimated, and a 95% CI will be reported. |
From randomization to the earlier progression or death due to any cause, assessed up to 5 years
|
|
Overall response rate (ORR)
기간: Up to 5 years
|
ORR will be assessed among patients who received at least one dose of protocol therapy using RECIST v 1.1 criteria. ORR will be defined as the number of patients with complete response (CR) and partial response (PR) divided by the number of treated patients. ORR will be calculated based on the definition by arm and will be reported with 95% CI. |
Up to 5 years
|
|
Clinical benefit rate (CBR)
기간: Up to 5 years
|
CBR will be defined as CR, PR, or stable disease per RECIST v 1.1. CBR will be calculated based on the definition by arm and will be reported with 95% CI. |
Up to 5 years
|
|
Duration of response (DOR)
기간: From the first occurrence of a documented objective response to disease progression or death, whichever occurs first, assessed up to 5 years
|
DOR will be assessed by RECIST v1.1. DOR will be characterized with the method of Kaplan-Meier and will be compared between the two treatment arms using stratified log-rank test. The HR will be estimated, and a 95% CI will be reported. |
From the first occurrence of a documented objective response to disease progression or death, whichever occurs first, assessed up to 5 years
|
|
Incidence of adverse events (AEs)
기간: Up to 30 days after last dose of study drug
|
AEs will be graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The percentage of patients with toxicities will be tabulated. The 90% CI for the true probability of observing toxicity of ≥ grade 4 on a given arm will be no wider than 12.3 %. The probability of observing ≥ 1 toxicity on a given arm with a true rate of 1% is 85.5%. |
Up to 30 days after last dose of study drug
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18) summary score
기간: At baseline and at 3, 6 and 12 months
|
Change in patient reported FBISI-18 score will be compared between arms using a two-sample t-test. Assessment time will be considered as a continuous variable if there is a linear trend in quality of life (QOL) assessments over time or a set of dummy variables if a non-linear trend exists. Patient demographics and disease characteristics will be adjusted in the mixed effect model. A t-test will be performed to explore change of FBISI-18 summary score. |
At baseline and at 3, 6 and 12 months
|
|
Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) summary score
기간: At baseline and at 3, 6 and 12 months
|
Change in patient reported FACIT-F score will be compared between arms using a two-sample t-test. Mixed effect models will be constructed to estimate the time profile of FACIT-F in the two arms and to evaluate treatment-by-time interactions. Assessment time will be considered as a continuous variable if there is a linear trend in QOL assessments over time or a set of dummy variables if a non-linear trend exists. Patient demographics and disease characteristics will be adjusted in the mixed effect model. |
At baseline and at 3, 6 and 12 months
|
|
Change in quality-adjusted survival (assessed by the European Quality of Life Five Dimension Five Level scale [EQ-5D-5L]).
기간: At baseline and at 3, 6 and 12 months
|
Change in patient reported EQ-5D-5L will be compared between the arms using a two-sample t-test. Quality-adjusted survival (assessed by the EQ-5D-5L), will be analyzed with quality-adjusted time without symptoms or toxicity. |
At baseline and at 3, 6 and 12 months
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Monika Joshi, ECOG-ACRIN Cancer Research Group
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 신생물
- 조직학적 유형에 따른 신생물
- 신생물, 선상 및 상피
- 암종
- 암종, 과도기 세포
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 조사 기술
- 임상 실험실 기술
- 진단 기술 및 절차
- 진단
- 탄화수소
- 사이클로 파라핀
- 탄화수소, alicyclic
- 탄화수소, 순환
- 테르펜
- 무기 화학 물질
- 염소 화합물
- 질소 화합물
- 조정 복합체
- 박습니다
- 사이클로 데카네
- Diterpenes
- 데 옥시 시티 딘
- 시티 딘
- 피리 미딘 뉴 클레오 시드
- 피리 미딘
- 강요
- 궤조
- 건강 관리 경제 및 조직
- 화학 기술, 분석
- 스펙트럼 분석
- 금속, 무겁다
- 백금 화합물
- 전환 요소
- 경제학
- 도세탁셀
- 젬시타빈
- 카르보플라틴
- 파클리탁셀
- 시스플라틴
- 1,2-디아미노사이클로헥산백금 II 구연산염
- 시편 처리
- 펨브 롤리 주맙
- 자기 공명 분광법
- 백금
- Sacituzumab Govitecan
- 구실
기타 연구 ID 번호
- NCI-2024-06208
- U10CA180820 (미국 NIH 보조금/계약)
- NCI-2024-06208 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
- EA8231 (기타 식별자: CTEP)
- EA8231 (기타 식별자: ECOG-ACRIN Cancer Research Group)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .